Related Experiment Video
Updated: Jan 31, 2026

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
Published on: May 25, 2020
Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and
Victoria M Addis1, Eydie Miller-Ellis1
1Division of Glaucoma, Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA, USA, miller@uphs.upenn.edu.
Abstract:
Latanoprostene bunod (LBN) 0.024%, a modified prostaglandin analog, was approved on November 2, 2017, for the reduction of IOP in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). LBN works by combining the IOP-lowering effects of the prostaglandin analogs (through the uveoscleral pathway) with nitric oxide-induced relaxation of the trabecular meshwork and Schlemm's canal. Nitric oxide-induced relaxation of the trabecular meshwork and Schlemm's canal leads to increased outflow through the trabecular meshwork and thus lowering of IOP. LBN has now been shown in multiple clinical studies to be effective and safe. In this article, we summarize the clinical trials that led to LBN's approval as well as the comparative studies that have been done to evaluate the efficacy of this drug as compared to other US Food and Drug Administration (FDA)-approved therapies for OAG and OHT. We then review the side effects of treatment that were seen in each of these studies. Finally, we will attempt to discuss the place of this drug in therapy for patients with OAG.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Design Example: Traverse Angle Computations
Glaucoma: Overview
Contact Angle
The adhesive force is the molecular force between molecules of different materials, that is, between the molecules of the solid and the liquid. The cohesive...
Gene Therapy

